A clinical study (NCT01295827) found that after all patients with advanced melanoma were treated with pembrolizumab PD-1, patients with high PD-L1 expression had a higher objective response rate, and longer progression-free survival (PFS) and OS 46. This evidence concerns the gene PDCD1 and melanoma.